Skip to main content

Table 1 Summary of data collection

From: A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C

Data type Information recorded Time point
Demographics Age, gender, postcode, Indigenous status Enrolment
Lifestyle Self-reported injecting drug use, self-reported alcohol in-take, self-reported housing status, self-reported reuse of a needle/syringe, self-reported prescribed opioid substitution therapy, risk of treatment disruption (including imprisonment) Enrolment
Clinical Hepatitis C history, previous treatment, comorbidities, HCV genotype and RNA level, liver function tests, liver fibrosis assessment Treatment prescription
Treatment DAA therapy and duration prescribed, treatment setting, type of prescriber, concurrent medication, other concurrent HCV management interventions Treatment prescription
Medication adherence Self-reported adherence to therapy Weekly during treatment course
Quality of life Self-reported quality of life (QoL) score (EQ-5D-5L) 0, 3, 6, 12 and 24 months after treatment initiation
Outcomes HCV RNA PCR, all re-collected laboratory and imaging results, self-reported injecting drug use, 3 months after treatment completion